Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31141395 | 0.87 | CHRM2 (0.42) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL2910823 | 0.87 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1ATMSIGMAR1MEN1 | |
| SCHEMBL31351572 | 0.85 | ALDH1A1 (0.40) | ALDH1A1MEN1KMT2ACHRM2CHRM4 | |
| SCHEMBL17517700 | 0.80 | L3MBTL1 (0.48) | ALDH1A1L3MBTL1ATMSIGMAR1MEN1 | |
| SCHEMBL183706 | 0.79 | ALDH1A1 (0.52) | ALDH1A1L3MBTL1ATMSIGMAR1MEN1 | |
| SCHEMBL15315336 | 0.78 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1ATMSIGMAR1MEN1 | |
| Hydrochloric Acid SCHEMBL183705 | 0.78 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1ATMSIGMAR1MEN1 | |
| SCHEMBL183598 | 0.77 | ALDH1A1 (0.50) | ALDH1A1L3MBTL1ATMSIGMAR1MEN1 | |
| SCHEMBL159259 | 0.77 | L3MBTL1 (0.54) | ALDH1A1L3MBTL1ATMSIGMAR1MEN1 | |
| SCHEMBL16903450 | 0.77 | KDM4E (0.47) | ALDH1A1L3MBTL1SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287071-A1 | CLASS OF IMIDAZOLIDINOPYRIMIDONE COMPOUNDS AND USE THEREOF IN TREATMENT OF HSCLPP-MEDIATED DISEASES | CHENGDU MITORTHERA PHARMACEUTICAL CO., LTD. (CN) | 2024-08-29 | — | — | US | disclosed |
| US-10221182-B2 | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-03-05 | — | — | US | disclosed |
| US-10221182-B2 | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2019-03-05 | — | — | US | disclosed |
| US-20180030055-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-02-01 | — | — | US | disclosed |
| US-20180030055-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-02-01 | — | — | US | disclosed |
| US-20180030055-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2018-02-01 | — | — | US | disclosed |
| WO-2016126869-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016126869-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | RUGEN HOLDINGS (CAYMAN) LIMITED (KY) | 2016-08-11 | — | — | WO | disclosed |
| US-9400280-B2 | Piperidine derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9400280-B2 | Piperidine derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | HOFFMANN-LA ROCHE, INC. | 2011-08-18 | — | — | US | disclosed |
| EP-2334677-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2010-08-12 | — | — | US | disclosed |
| WO-2010090875-A1 | DERIVATIVES OF N2-(3-PYRIDIL OR PHENYL)-N4-(4-PIPERIDYL)-2,4-PYRIMIDINEDIAMINE USEFUL IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE OR PROLIFERATIVE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2010022076-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| EP-2139888-A2 | IMIDAZOÝ1,2-A¨PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008121687-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287071-A1 | CLASS OF IMIDAZOLIDINOPYRIMIDONE COMPOUNDS AND USE THEREOF IN TREATMENT OF HSCLPP-MEDIATED DISEASES | PRCP, TSLP, HPN | ALDH1A1 2702/4885L3MBTL1 2519/4885ATM 3773/4885 |
| US-20100204208-A1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | PRKCH, PRKCA, PRKCB | ALDH1A1 4361/4885L3MBTL1 2767/4885ATM 433/4885 |
| US-20100144751-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS | PIM1, PIM3, PIM2 | ALDH1A1 405/4885L3MBTL1 1756/4885ATM 1367/4885 |
| US-20180030055-A1 | 3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS | GRIN3A, GRIN1, GRIN2A | ALDH1A1 1293/4885L3MBTL1 3628/4885ATM 3412/4885 |
| US-10221182-B2 | 3,3-difluoro-piperidine derivatives as NR2B NMDA receptor antagonists | GRIN3A, GRIN1, GRIN2A | ALDH1A1 1293/4885L3MBTL1 3628/4885ATM 3412/4885 |
| US-20110144085-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM1, PIM2, PIM3 | ALDH1A1 2440/4885L3MBTL1 1308/4885ATM 455/4885 |
| US-20110201605-A1 | HETEROARYL SUBSTITUTED PIPERIDINES | APP, HPGDS, PSEN1 | ALDH1A1 1444/4885L3MBTL1 705/4885ATM 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.